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Abstract
Amulticenter Korean Prostate Cancer Database (K-CaP) has been established to provide information regarding Korean patients with
prostate cancer (PCa). We used the K-CaP registry to investigate the value of age and comorbidity for predicting cancer-speciﬁc
mortality (CSM) and other-cause mortality (OCM) according to risk grouping.
The K-CaP registry includes 2253 patients who underwent radical prostatectomy (RP) between May 2001 and April 2013 at 5
institutions. Preoperative clinicopathologic data were collected and stratiﬁed according to the National Comprehensive Cancer
Network risk criteria. Survival was evaluated using Gray’s modiﬁed log-rank test according to risk category, age (<70 years vs ≥70
years), and Charlson comorbidity index (CCI) (0 vs ≥1).
The median follow-up was 55.0 months (interquartile range: 42.0–70.0 months). Competing-risk regression analysis revealed that,
independent of CCI, ≥70-year-old high-risk patients had signiﬁcantly greater CSM than <70-year-old high-risk patients (P= .019).
However, <70-year-old high-risk patients with a CCI of ≥1 had similar CSM relative to ≥70-year-old patients. Survival was not
affected by age or CCI among low-risk or intermediate-risk patients. Multivariate analysis revealed that a CCI of≥1was independently
associated with a higher risk of CSM (P= .003), while an age of ≥70 years was independently associated with a higher risk of OCM
(P= .005).
Age and comorbidity were associated with survival after RP among patients with high-risk PCa, although these associations were
not observed among low-risk or intermediate-risk patients. Therefore, older patients with high-risk diseases and greater comorbidity
may require alternative multidisciplinary treatment.
Abbreviations: ADT= androgen deprivation therapy, BMI= bodymass index, CCI=Charlson comorbidity index, CSM= cancer-
speciﬁc mortality, K-CaP = Korean Prostate Cancer Database, NCCN = National Comprehensive Cancer Network, OCM = other-
cause mortality, PCa = prostate cancer, PSA = prostate-speciﬁc antigen, RP = radical prostatectomy, RT = radiotherapy.
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11. Introduction
Prostate cancer (PCa) is characterized by a heterogeneous disease
landscape, with low-risk localized PCa having an exceptionally
protracted natural history. However, broad variations are
observed in the oncologic outcomes for high-risk PCa, and the
optimal treatment modality remains unclear.[1] During the last
decade, radiotherapy (RT) plus androgen deprivation therapy
(ADT) have been the mainstay of management for localized high-
risk PCa. However, radical prostatectomy (RP) has become a
potentially curative treatment for localized high-risk PCa because
of improvements in surgical technique, anesthesia, and postop-
erative care.[2] Nevertheless, there is no consensus regarding the
optimal treatment for high-risk PCa, which is presumably related
to inappropriate patient grouping that is caused by inadequate
analysis of risk and predictive factors. Thus, more prognostic
parameters are needed to supplement the use of conventional risk
prediction based on prostate-speciﬁc antigen (PSA) status,
Gleason score, and clinical stage.[3–5] Moreover, prolonged life
Hah et al Medicine (2018) 97:42 Medicineexpectancy has increased the proportion of individuals with
excellent performance status relative to their biologic age.
Therefore, given the importance of life expectancy after PCa
treatment, patient age, and comorbidity burden are essential
factors to consider when making treatment decisions.[6,7]
The overall incidence and mortality of PCa is higher among
Asianmen than amongWesternmen, which is predictably related
to genetic differences and acquired dissimilarities, such as diet
and lifestyle.[8–11] Moreover, developing Asian countries have
lower rates of PSA screening, which may explain the more
aggressive PCa features and greater proportion of metastasis at
diagnosis among Asian men.[12,13] Therefore, it would be difﬁcult
to adopt Western management guidelines for use among Asian
men without modiﬁcation.
The internet-based multicenter Korean Prostate Cancer
Database (K-CaP) was established in 2011, and is the ﬁrst
registry to provide comprehensive data regarding Korean PCa
patients who underwent RP.[10] Thus, we used the K-CaP registry
to assess the value of age and comorbidity for predicting cancer-
speciﬁc mortality (CSM) and other-cause mortality (OCM)
among patients with PCa who underwent RP, with stratiﬁcation
according to the National Comprehensive Cancer Network
(NCCN) risk criteria.2. Methods
2.1. Patient selection
Clinicopathologic data and oncologic outcomes for 3815
patients who underwent RP between May 2001 and April
2013 were retrieved from the K-CaP registry. The K-CaP registry
is an internet-based, observational, and automated data-entry
system that has been implemented at 5 high-volume Korean
institutions: Asan Medical Center, Samsung Medical Center,
Seoul National University Bundang Hospital, Seoul St Mary’s
Hospital, and Yonsei University Severance Hospital. Patients
with incomplete data and patients who received neoadjuvant
therapy were excluded from the present study. Preoperative
clinicopathologic data were used to stratify 2253 patients
according to the 2018 NCCN risk criteria, as follows: low
risk=T-stage T1-T2a, Gleason score 6, and PSA <10ng/mL;
intermediate risk=T-stage T2b-T2c, or Gleason score 7 (both 3
+4 and 4+3), or PSA 10 to 20ng/mL; high risk=T-stage ≥T3a, or
Gleason score ≥8, or PSA >20ng/mL.[14] The present study’s
retrospective protocol was reviewed and approved by the Yonsei
University Health System Ethics Committee, which waived the
requirement for informed consent (2016-0389-001). All study
procedures complied with the principles of the 1964 Declaration
of Helsinki and its 2008 update.2.2. Assessments of clinicopathologic variables
The collected clinicopathologic data included age at the
operation, body mass index (BMI), medical history, Gleason
score, serum PSA level at the diagnosis, clinical T and N stages,
interval for progression to castration-resistant PCa, and follow-
up period. Each patient’s comorbidity proﬁle was analyzed using
the Charlson comorbidity index (CCI), which is the most widely
used comorbidity index in surgical settings. The CCI scoring
system is based on the weighted number and severity of 19
comorbidities,[15] and the present study compared absolute
scores between the various patient groups. The intervals to CSM
and OCMwere deﬁned based on the times from RP to death that2was attributed to PCa or to other causes, respectively. Patient
survival and causes of death were investigated using the National
Cancer Registry Database or institutional electronic medical
records.
The decisions to perform RP, as well as adjuvant or salvage
therapies, were made based on each physician’s discretion and the
patient’s preference. In general, RP was recommended for
patients who desired surgical treatment or who were considered
reasonable surgical candidates based on favorable clinical
characteristics. The RP was performed using open retropubic,
laparoscopic, or robot-assisted laparoscopic modalities, and the
extent of pelvic lymph node dissection was based on the patient’s
risk category.2.3. Statistical analysis
The effects of age and comorbidity were evaluated by categoriz-
ing the patients according to age (<70 years vs ≥70 years) and
CCI (0 vs ≥1). Predictors of survival were evaluated using Fine
and Gray’s modiﬁed log-rank test for each risk category
according to age and CCI grouping. All statistical analyses were
performed using IBM SPSS software (version 21.0; IBM
Corporation, Armonk, NY) and R statistical package (version
3.2.0; Institute for statistics and mathematics, Vienna, Austria).
Differences with a P-value of <.05 were considered statistically
signiﬁcant.3. Results
3.1. Clinicopathologic features
Table 1 shows the clinicopathologic features of the 2253 patients
who were included in the ﬁnal analysis. The proportion of
patients with a CCI of ≥1 was higher among ≥70-year-old men
than among <70-year-old men (25.2% vs 17.5%, P < .001).
However, the younger group had more favorable preoperative
Gleason score and T-stage than the older group. No signiﬁcant
age-related differences were observed in BMI, serum PSA levels,
NCCN risk grouping, or follow-up period.3.2. Competing risk analysis
Gray’s competing risk regression analysis revealed that≥70-year-
old patients had a signiﬁcantly higher cumulative CSM rate than
<70-year-old patients, with the exemption of low-risk patients
(P= .002) (Fig. 1). When CCI was taken into account, high-risk
<70-year-old patients with CCI ≥1 had comparable cumulative
CSM rates compared to ≥70-year-old patients, while the
cumulative CSM rate was signiﬁcantly higher in ≥70-year-old
patients with CCI ≥1 (P= .019; Fig. 2). However, CSM was not
affected by age or CCI in the low-risk and intermediate-risk
groups.
3.3. Predictors of survival
The Fine and Gray’s analysis revealed that the risk of overall
mortality was associated with older age (hazard ratio [HR]:
2.544, 95% conﬁdence interval [CI]: 1.096–5.908; P= .03) and a
CCI of ≥1 (HR: 2.409, 95% CI: 1.075–5.397; P= .033).
Furthermore, a CCI of ≥1 was associated with a higher risk of
CSM (HR: 4.872, 95%CI: 1.686–14.08; P= .003), and an age of
≥70 years was associated with a higher risk of OCM (HR: 10.44,
95% CI: 2.064–52.85; P= .005) (Table 2).
Table 1
Patient characteristics.
Overall Age ≥70 y Age <70 y P
N 2253 588 (26.1%) 1665 (73.9%)
Age, y 65.0 (60.0–70.0) 72.0 (71.0–74.0) 63.0 (58.0–66.0) <.001
BMI, kg/m2 24.4 (22.7–26.1) 24.4 (22.3–26.0) 24.4 (22.8–26.1) .567
Comorbidity
CCI (≥1) 440 (19.5%) 148 (25.2%) 292 (17.5%) <.001
DM 307 (13.6%) 104 (17.7%) 203 (12.2%) .001
HTN 803 (35.6%) 257 (43.7%) 546 (32.8%) <.001
Biopsy Gleason sum .007
6 984 (43.7%) 233 (39.6%) 751 (45.1%)
7 797 (35.4%) 209 (35.5%) 588 (35.3%)
8 472 (20.9%) 146 (24.8%) 326 (19.6%)
PSA, ng/mL 7.15 (5.04–11.6) 7.73 (5.13–12.4) 6.98 (5.0–11.4) .403
NCCN risk criteria .465
Low 603 (26.8%) 133 (22.6%) 470 (28.2%)
Intermediate 986 (43.8%) 264 (44.9%) 722 (43.4%)
High 664 (29.5%) 191 (11.5%) 473 (28.4%)
Pathologic T stage .010
T2 1518 (67.4%) 366 (62.4%) 1152 (69.2%)
T3 729 (32.4%) 220 (37.5%) 509 (30.6%)
T4 4 (0.2%) 1 (0.2%) 3 (0.2%)
Pathologic N stage (N1) 146 (6.5%) 39 (6.9%) 107 (6.6%) .810
Progression to CRPC 271 (12.0%) 52 (8.9%) 219 (13.2%) .006
Follow-up period, mo 55.0 (42.0–70.0) 51.0 (37.0–66.0) 56.0 (43.0–72.0) .154
Data are numbers (%) and medians (interquartile range, IQR).
BMI=body mass index, CCI=Charlson comorbidity index, CRPC= castration-resistant prostate cancer, DM=diabetes mellitus, GS=Gleason score, HTN=hypertension, NCCN=National Comprehensive
Cancer Network, PSA=prostate-speciﬁc antigen.
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Advancements in the understanding of tumor microbiology and
treatment modalities have generated increases in the 5-year
relative survival rates for many cancers during the last decade.[16]
Furthermore, rates of early diagnosis have been enhanced by
changes in health perception, healthcare improvements, and
advances in medical imaging. These developments will likely
prolong the human lifespan, which highlights the importance of
considering age and comorbidity when selecting treatment for
PCa. The present study evaluated multicenter data from the K-
CaP database and compared the rates of CSM and OCM among
patients who were stratiﬁed based on age and comorbidity. Our
competing-risk analysis revealed that in high-risk patients, older
age and comorbidities were signiﬁcantly associated with
cumulative CSM. Notably, <70-year-old patients with CCI ≥1
had comparable cumulative CSM rates compared to ≥70-year-
old patients.
The 2018 NCCN guideline recommend basing treatment
decisions on the patient’s life expectancy and the number and
type of recurrence risk factors.[14] However, given the protracted
natural history of PCa, survival is strongly associated with age
and comorbidity. Thus, although the 2018 NCCN guideline
recommend RP if the patient’s life expectancy is expected to be
>10 years, this is an imprecise and unpredictable proxy.
Moreover, overall survival is strongly affected by CCI.[17]
Therefore, comorbidity- and age-adjusted reference values are
needed to guide counseling and the selection of surgical
treatment.[18]
Briganti et al retrospectively investigated the risks of CSM and
OCM in high-risk patients with PCa treated with RP, and
reported that age and comorbidity were the major determinants
of OCM. OCM was the leading cause of death in all patient
subgroups with the exemption of young and healthy patients.3This observation lends support to the notion that these patients
may more likely to beneﬁt from aggressive surgical treatment
compared to older and unhealthy patients who have a higher risk
of OCM.[6] Sivaraman et al also analyzed the beneﬁts of RP for
older patients with high-risk PCa according to their CCI, and
reported that a higher OCM risk was observed among older
patients with a CCI of ≥2, although older patients with high-risk
PCa and fewer comorbidities appeared to beneﬁt from RP.[7]
Those studies provided valuable evidence that age and CCI
should be considered when predicting survival among men with
high-risk PCa, although those studies did not include low-risk
and intermediate-risk patients. Thus, the present study evaluated
Korean patients with low-, intermediate-, and high-risk disease,
and revealed that age and comorbidity were only signiﬁcant
prognostic factors for patients with high-risk disease. Several
other studies have addressed the value of comorbidity for
predicting CSM and OCM outcomes among Western patients
with PCa who are undergoing RP,[19–23] although their ﬁndings
may not reﬂect the expected outcomes among Asian men.
Nevertheless, because age and comorbidity were not signiﬁcant
prognostic factors among Korean patients with low-risk and
intermediate-risk disease, the conventional risk factors (PSA
status, Gleason score, and clinical stage) may provide appropriate
risk stratiﬁcation in this setting. However, the heterogeneous
nature of high-risk PCa highlights the importance of considering
all possible prognostic factors to optimize treatment selection.
Therefore, our ﬁndings indicate that age and comorbidity should
be considered during the management of Korean men with high-
risk PCa.
Froehner et al[18] and Boehm et al[24] have reported conﬂicting
ﬁndings regarding the prognostic value of age and comorbidity
among patients with PCa. For example, Froehner et al claimed
that competing mortality was associated with comorbidities
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Figure 1. Cumulative survival based on Gray’s competing-risk regression analysis of cancer-speciﬁc mortality according to age group (≥70 years vs<70 years) in
the (A) low-risk, (B) intermediate-risk, and (C) high-risk groups.
Hah et al Medicine (2018) 97:42 Medicineamong older patients (>70 years), such as peripheral vascular
disease, cerebrovascular disease, and current smoking status.
In contrast, Boehm et al suggested that age and CCI did not
inﬂuence OCM or life expectancy. These discrepant ﬁndings
may be related to differences in cohort selection, as Froehner
et al analyzed patients with PCa who underwent surgical
treatment and Boehm et al analyzed ≥66-year-old patients
with nonmetastatic PCa who were stratiﬁed according to
treatment type. As patients with high-risk PCa experience
heterogeneous survival outcomes, the variable ﬁndings
from these studies indicate that age and comorbidity should
not be interpreted blindly to avoid unintended bias. The
present study aimed to overcome the limitations of retrospective
analyses using Fine and Gray’s modiﬁed log-rank test, which
provided data according to risk category, age, and CCI grouping
to help identify which Korean patients are the best candidates for
surgery.4The strengths of the present study are the inclusion of a large
sample of patients who underwent RP for PCa from the K-CaP
database, which is the largest multicenter nationally representa-
tive Korean registry. This perspective is important, as Asian men
have more aggressive PCa features at their diagnosis than
Western men,[8,25–27] although there are no multicenter data
regarding the prognostic value of age and comorbidity among
Asian patients with PCa. Thus, the present study provides
valuable regional data that can better guide the management of
PCa in Korean. However, the present study also has several
limitations. First, selection bias is possible, as only 2253 of 3815
patients were considered eligible for the analysis, which was
mainly related to incomplete clinicopathologic data that were
generated from the institution’s different data collection proto-
cols. Nevertheless, the large number of exclusions was necessary
to preserve data quality and enhance the prognostic analysis. A
second limitation is that the cohort only included patients who
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Figure 2. Cumulative survival analysis based on Gray’s competing-risk regression analysis of cancer-speciﬁc mortality according to age and comorbidity grouping
(≥70 years vs <70 years; CCI: 0 vs ≥1) in the (A) low-risk, (B) intermediate-risk, and (C) high-risk groups.
Table 2
Predictors of survival.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Overall mortality
Age (≥70 y) 2.898 1.809–4.642 <.001 2.544 1.096–5.908 .030
CCI (≥1) 2.484 1.105–5.535 .028 2.409 1.075–5.397 .033
PSA 0.997 0.979–1.016 .759 0.999 0.961–1.038 .963
Pathologic GS (≥8) 1.106 0.603–2.027 .746 0.481 0.107–2.175 .342
Pathologic T stage (≥pT3) 1.134 0.699–1.840 .611 0.747 0.349–2.128 .862
Cancer-speciﬁc mortality
Age (≥70 y) 1.872 0.957–3.663 .057 0.892 0.254–3.141 .859
CCI (≥1) 4.848 1.680–13.99 .004 4.872 1.686–14.08 .003
PSA 0.999 0.977–1.022 .939 1.001 0.956–1.047 .976
Pathologic GS (≥8) 1.252 0.571–2.745 .574 0.978 0.846–1.134 .762
Pathologic T stage (≥pT3) 1.221 0.638–2.337 .546 1.003 0.344–2.929 .995
Other cause mortality
Age (≥70 y) 4.768 2.352–9.665 <.001 10.44 2.064–52.85 .005
CCI (≥1) 0.632 0.127–3.136 .574 1.654 0.333–8.214 .538
PSA 0.994 0.964–1.025 .705 1.003 0.948–1.061 .925
Pathologic GS (≥8) 0.932 0.357–2.436 .886 1.313 0.238–7.242 .754
Pathologic T stage (≥pT3) 1.034 0.498–2.148 .928 0.625 0.117–3.328 .580
Data are expressed as means± standard deviations or number of patients (%), as appropriate.
CCI=Charlson comorbidity index, CI=conﬁdence interval, GS=Gleason score, HR=hazard ratio, PSA=prostate-speciﬁc antigen.
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[7] Sivaraman A, Ordaz Jurado G, Cathelineau X, et al. Older patients with
Hah et al Medicine (2018) 97:42 Medicineunderwent RP, and men who received other treatments were
excluded. Although many researchers have indicated that RP
provides acceptable results for patients with low-risk, intermedi-
ate-risk, and high-risk PCa, there is no consensus regarding
whether RP is superior to other treatments.[28–30] Thus, further
studies are needed to compare RP and other treatments. A third
limitation is that the patients were treated at multiple institutions,
and the survival outcomes may have been inﬂuenced by
variations in surgeon experience and skill.[31]5. Conclusion
The present study revealed that age and comorbidity could
predict survival among patients with high-risk PCa who
underwent RP, although this relationship was not observed
among patients with low-risk or intermediate-risk disease.
However, given the protracted natural history of PCa, studies
are needed to evaluate the risk of OCM among elderly patients
with comorbidities and high-risk disease. Alternative multidisci-
plinary treatment may be needed for patients who are not
expected to beneﬁt from RP in this setting.Author contributions
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